BrainsWay (NASDAQ:BWAY) Receives “Buy” Rating from HC Wainwright

BrainsWay (NASDAQ:BWAY)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $16.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 71.12% from the company’s previous close.

Separately, Northland Securities increased their price objective on shares of BrainsWay from $11.00 to $12.50 and gave the company an “outperform” rating in a research report on Thursday, October 3rd.

BrainsWay Stock Up 2.2 %

Shares of NASDAQ BWAY opened at $9.35 on Monday. The business’s 50 day moving average price is $9.84 and its two-hundred day moving average price is $8.24. The company has a market cap of $175.90 million, a PE ratio of 93.51 and a beta of 1.23. BrainsWay has a twelve month low of $4.61 and a twelve month high of $10.98.

BrainsWay (NASDAQ:BWAY) last posted its earnings results on Tuesday, November 12th. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%. The business had revenue of $10.50 million for the quarter, compared to analyst estimates of $10.07 million. During the same period in the previous year, the firm earned ($0.01) EPS. As a group, research analysts anticipate that BrainsWay will post 0.06 EPS for the current fiscal year.

Institutional Investors Weigh In On BrainsWay

Several institutional investors have recently made changes to their positions in the stock. Acadian Asset Management LLC raised its holdings in shares of BrainsWay by 48.1% during the 2nd quarter. Acadian Asset Management LLC now owns 259,787 shares of the company’s stock worth $1,567,000 after buying an additional 84,371 shares in the last quarter. Good Life Advisors LLC lifted its stake in BrainsWay by 65.5% in the 3rd quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock valued at $516,000 after purchasing an additional 22,080 shares during the last quarter. Perritt Capital Management Inc acquired a new stake in BrainsWay in the second quarter valued at approximately $121,000. Finally, Rhumbline Advisers grew its stake in shares of BrainsWay by 10.3% during the second quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock worth $110,000 after buying an additional 1,695 shares during the last quarter. 30.11% of the stock is currently owned by institutional investors.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.